US5679666A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
Assignee: Alcon Research LLC
•
Filing: 1994-11-21
•
Granted: 1997-10-21
•
Expires: 2014-11-21
Abstract
Abstract Methods and formulations for treating ocular neovascularization using angiostatic steroids are disclosed.
Inventors
- 👤 Abbot F. Clark
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 03:49
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61K31/573; A61K31/565; C; C07; C07J; C07J11/00; C07J3/00; C07J41/00; C07J41/0005; C07J41/0027; C07J5/00; C07J5/0046; C07J5/0053; C07J51/00; C07J9/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
41 words
A method for preventing and treating ocular neovascularization, which comprises: administering, topically, systemically, or intraocularly, to a host in need thereof, a pharmaceutically effective amount of an angiostatic steroid selected from the group consisting of: 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate, 4,9(11)-Pregnadien-17a,21-diol-3,20-dione,11-Epicortisol, 17alpha-Hydroxyprogesterone, and Tetrahydrocortexolone. (THS).
Claim 2
Independent Claim
41 words
A method for preventing and treating ocular neovascularization, which comprises: administering, topically, systemically, or intraocularly, to a host in need thereof, a pharmaceutically effective amount of an angiostatic steroid selected from the group consisting of: 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate, 4,9(11)-Pregnadien-17a,21-diol-3,20-dione,11-Epicortisol, 17alpha-Hydroxyprogesterone, and Tetrahydrocortexolone. (THS).
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate.
Claim 4
Dependent Claim
11 words
The method of claim 1 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17a,21-diol-3,20-dione.
Claim 5
Dependent Claim
21 words
The method of claim 1 wherein the angiostatic steroid is administered at a concentration of about 0.01 to 10.0 weight percent.
Claim 6
Dependent Claim
19 words
The method of claim 4 wherein the angiostatic steroid is administered at a concentration of about 0.1-5.0 weight percent.
Claim 7
Independent Claim
49 words
A method for preventing and treating neovascularization of the tissues in the front of the eye, which comprises: administering, topically, systemically, or intraocularly to a host in need thereof, a pharmaceutically effective amount of an angiostatic steroid selected from the group consisting of: 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate, 4,9(11)-Pregnadien-17a,21-diol-3,20-dione,11-Epicortisol, 17alpha-Hydroxyprogesterone, and Tetrahydrocortexolone (THS).
Claim 8
Independent Claim
49 words
A method for preventing and treating neovascularization of the tissues in the front of the eye, which comprises: administering, topically, systemically, or intraocularly to a host in need thereof, a pharmaceutically effective amount of an angiostatic steroid selected from the group consisting of: 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate, 4,9(11)-Pregnadien-17a,21-diol-3,20-dione,11-Epicortisol, 17alpha-Hydroxyprogesterone, and Tetrahydrocortexolone (THS).
Claim 9
Dependent Claim
11 words
The method of claim 6 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate.
Claim 10
Dependent Claim
11 words
The method of claim 6 wherein the angiostatic steroids is 4,9(11)-Pregnadien-17a,21-diol-3,20-dione.
Claim 11
Dependent Claim
21 words
The method of claim 6 wherein the angiostatic steroid is administered at a concentration of about 0.01 to 10.0 weight percent.
Claim 12
Dependent Claim
13 words
The method of claim 7 wherein the concentration is about 0.1-5.0 weight percent.
Claim 13
Dependent Claim
13 words
The method of claim 9 wherein the tissue being treated is the cornea.
Claim 14
Independent Claim
49 words
A method for preventing and treating neovascularization of the tissues of the back of the eye, which comprises: administering, topically, systemically: or intraocularly, to a host in need thereof, a pharmaceutically effective amount of an angiostatic steroid selected from the group consisting of: 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate, 4,9(11)-Pregnadien-17a,21-diol-3,20-dione,11-Epicortisol, 17alpha-Hydroxyprogesterone, and Tetrahydrocortexolone (THS).
Claim 15
Independent Claim
49 words
A method for preventing and treating neovascularization of the tissues of the back of the eye, which comprises: administering, topically, systemically: or intraocularly, to a host in need thereof, a pharmaceutically effective amount of an angiostatic steroid selected from the group consisting of: 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate, 4,9(11)-Pregnadien-17a,21-diol-3,20-dione,11-Epicortisol, 17alpha-Hydroxyprogesterone, and Tetrahydrocortexolone (THS).
Claim 16
Dependent Claim
11 words
The method of claim 12 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17a,21-diol-3,20-dione.
Claim 17
Dependent Claim
21 words
The method of claim 13 wherein the angiostatic steroid is administered at a concentration of about 0.01 to 10.0 weight percent.
Claim 18
Dependent Claim
21 words
The method of claim 13 wherein the angiostatic steroid is administered at a concentration of about 0.1 to 5.0 weight percent.
Claim 19
Dependent Claim
16 words
The method of claim 13 wherein the tissue being treated is the retina or the subretina.
Claim 20
Dependent Claim
13 words
The method of claim 13 wherein the tissue being treated is the macula.
Claim 21
Dependent Claim
15 words
The method of claim 14 wherein the tissue being treated is the optic nerve head.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-10-20 | 2001-04-21 | 2001-10-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-10-20 | 2005-04-21 | 2005-10-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-10-20 | 2009-04-21 | 2009-10-21 | $7700.00 | Window Closed / Lapsed |